301281.SZ
科源制药
SZSE · C 制造业 · CN
CNY 43.97
−0.20%Sep 3, 2026, 09:22 UTC
Keyuan Pharmaceutical's wholly-owned subsidiary Linuo Pharmaceutical received drug registration certificates from the National Medical Products Administration for Empagliflozin and Metformin Hydrochloride Extended-Release Tablets (III) and (IV), with approval numbers Guoyao Zhunzi H20265843 and H20265844.
Source:Aug 26, 2026, 10:28 UTC
Keyuan Pharmaceutical disclosed that as of June 30, 2026, it had invested 497 million yuan of its IPO proceeds into its fundraising projects, and changed the implementation of the isosorbide mononitrate project to purchase land and build new facilities, increasing total investment to 253 million yuan.
Source:Aug 3, 2026, 04:02 UTC
Multiple pharmaceutical companies announced that their drugs were selected in the 12th national centralized drug procurement.
Aug 3, 2026, 03:44 UTC
Linuo Pharmaceutical participated in the bidding for the 12th batch of national organized drug centralized procurement with volume-based purchase; products such as Isavuconazole Sulfate for Injection were provisionally selected, and the provisional selected enterprise for Betahistine Hydrochloride Tablets will later be changed to Linuo Pharmaceutical, with the procurement period ending on December 31, 2029.
Source:Aug 3, 2026, 03:44 UTC
Linuo Pharmaceutical, a wholly-owned subsidiary of Keyuan Pharmaceutical, received a drug supplementary application approval notice, and the marketing authorization holder of Betahistine Hydrochloride Tablets was changed to Linuo Pharmaceutical.
Source:Jul 13, 2026, 00:47 UTC
DrugFarm completed a $55 million Series D financing round.
Source: